All In Biotech

Drug Trial Radar · NCT05421429

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

An Open, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous (SC) Doses of KN057 in Subjects with Hemophilia a or B, with or Without Inhibitors

Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jul 7, 2022

Primary completion

Jan 17, 2024

Study completion Jan 17, 2024

Sponsor

Lead sponsor
Suzhou Alphamab Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous doses of KN057 in subjects with hemophilia A or B, with or without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). 24 adult participants 18 to 70 years of age with moderately severe to severe hemophilia A or hemophilia B (defined as FVIII or FIX activity ≤2%, respectively) with or without inhibitors (including 18 HA/HB patients without inhibitors and 6 HA/HB patients with inhibitors) are expected to be enrolled in this study during which they will receive prophylaxis treatment (defined as treatment by SC injection once weekly of KN057).

Conditions

  • Hemophilia

Interventions

  • KN057 doseⅠBiological

    KN057 subcutaneous (SC) injection

  • KN057 dose ⅡBiological

    KN057 SC injection

  • KN057 dose ⅢBiological

    KN057 SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of treatment emergent adverse events(TEAEs)Time frame: Day 1 up to Day 85
  2. Withdrawals due to TEAEsTime frame: Day 1 up to Day 85
  3. Number of Participants With Abnormal Laboratory Findings-HematologyTime frame: Day 1 up to Day 85
  4. Number of Participants With Abnormal Laboratory Findings-UrinalysisTime frame: Day 1 up to Day 85
  5. Number of Participants With Abnormal Laboratory Findings-Blood biochemistryTime frame: Day 1 up to Day 85
  6. Number of Participants With Abnormal Laboratory Findings-Coagulation testsTime frame: Day 1 up to Day 85
  7. Number of Participants With Clinically Significant Changes in Vital Signs DataTime frame: Day 1 up to Day 85
  8. Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)Time frame: Day 1 up to Day 85
  9. Number of Participants With Clinically Significant Changes in Physical Examination FindingsTime frame: Day 1 up to Day 85
  10. Number of Participants With Injection Site ReactionsTime frame: Day 1 up to Day 85

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • stitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.